Loteprednol Etabonate/Tobramycin

氯替泼诺/妥布霉素

Report date: 2025/11/14 13:46:50

Base Information

Drug NameLoteprednol Etabonate/Tobramycin
Drug Alias NameTobramycin/Loteprednol Etabonate妥布霉素氯替泼诺Tobramycin and Loteprednol Etabonate氯替泼诺妥布霉素妥布霉素/氯替泼诺 +[9] 
ClassificationSmall molecules > Steroids
Mechanisms of Action30S ribosomal subunit inhibitorsGlucocorticoid receptor agonistsCytosolic phospholipase A2 agonists
TargetsGlucocorticoid receptor30S ribosomal subunitCytosolic phospholipase A2
Therapy Area/IndicationsOcular inflammationInflammation
Global Approved IndicationsOcular inflammationInflammation
Approved Indications in ChinaOcular inflammation
Original Approved Country/TerritoryUnited States
Original Approved Date2004/12/14
Country/TerritoryUnited StatesMainland China
CombinationsYes Loteprednol EtabonateTobramycin
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBausch & Lomb
China Registration ClassN/A

Develop Information

Active CompaniesBausch & Lomb IncorporatedBausch And Lomb Inc
Inactive CompaniesN/A
Active IndicationsOcular inflammationInflammation
Inactive IndicationsN/A

Other Information

ATC CodeS03CA
Related LinksN/A